Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aerie Pharmaceuticals, Inc. (NASDAQ: AERI).

Full DD Report for AERI

You must become a subscriber to view this report.


Recent News from (NASDAQ: AERI)

Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar - Discovering Underlying Factors of Influence
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mirati Therapeutics, Inc. (NASDAQ:MRTX), comScore, Inc. (NASDAQ:SCOR), Nu...
Source: GlobeNewswire
Date: December, 04 2018 07:20
Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that ...
Source: Business Wire
Date: November, 07 2018 07:30
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2018 Results - Earnings Call Transcript
Aerie Pharmaceuticals Inc (AERI) Q3 2018 Earnings Conference Call November 6, 2018 5:00 PM ET Executives Rich Rubino – Chief Financial Officer Vince Anido – Chairman and Chief Executive Officer Tom Mitro – President and Chief Operating Officer Analysts ...
Source: SeekingAlpha
Date: November, 06 2018 23:44
Aerie Pharmaceuticals misses by $0.36, beats on revenue
Aerie Pharmaceuticals (NASDAQ: AERI ): Q3 Non-GAAP EPS of -$1.73 misses by $0.36 ; GAAP EPS of -$1.96 misses by $0.31 . Revenue of $7.3M beats by $1.42M . Press Release More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:27
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, November 6 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle ...
Source: Business Wire
Date: November, 06 2018 16:01
This May Be A Good Time To Pick Up Aerie Pharmaceuticals In 2018
Headquartered in Irvine, California, Aerie Pharmaceuticals ( AERI ) is an ophthalmic pharmaceutical company. The company is mainly focused on developing and commercializing therapies targeting glaucoma, retinal diseases, and other eye diseases. Aerie Pharmaceuticals today stands at the cusp ...
Source: SeekingAlpha
Date: October, 30 2018 22:59
Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. ...
Source: Business Wire
Date: October, 30 2018 07:30
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc. (NASDAQ:A...
Source: GlobeNewswire
Date: October, 25 2018 08:30
Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina, facility Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class thera...
Source: Business Wire
Date: October, 23 2018 06:30
Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average jumped 1.15 percent to close at 25,339.99, while the S&P 500 Index increased 1.42 perc...
Source: ACCESSWIRE IA
Date: October, 15 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1851.2551.1551.9550.60248,199
2018-05-1751.2551.1551.9550.60248,199
2017-06-2051.8550.5053.47550.20549,619
2017-06-1950.4051.4051.4549.175575,657
2017-06-1650.0550.0550.9049.451,292,036

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1435,341118,24729.8874Cover
2018-12-1370,495184,24238.2622Short
2018-12-1236,109128,45528.1102Cover
2018-12-1153,29789,47459.5670Short
2018-12-1060,49294,82363.7946Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AERI.


About Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Logo for Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $2,010,188,610 - 05/11/2018
  • Issue and Outstanding: 39,492,900 - 02/14/2018

 


Recent Filings from (NASDAQ: AERI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: AERI)

Daily Technical Chart for (NASDAQ: AERI)


Stay tuned for daily updates and more on (NASDAQ: AERI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AERI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AERI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AERI and does not buy, sell, or trade any shares of AERI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/